Related Experiment Video
Updated: Jun 19, 2026
07:58
Cell-Free DNA Integrity Analysis in Urine Samples
Published on: January 5, 2017
13.8K
Urinary DNA Methylation Test for Bladder Cancer Diagnosis
In Gab Jeong1, Sung-Cheol Yun2, Hong Koo Ha3
1Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
JAMA Oncology
|January 30, 2025
Summary
A new urinary DNA methylation test shows high sensitivity for detecting high-grade or invasive bladder cancer, outperforming existing methods. While effective for ruling out disease, its positive predictive value requires further study.
Area of Science:
- Oncology
- Biomarker Discovery
- Urology
Background:
- Accurate noninvasive biomarkers are crucial for early bladder cancer diagnosis.
- Current diagnostic methods like NMP22 and urine cytology have limitations.
Purpose of the Study:
- To evaluate the diagnostic performance of a urinary DNA methylation test.
- To compare its accuracy against NMP22 and urine cytology for bladder cancer detection.
Main Methods:
- Prospective multicenter study involving 1099 participants aged 40+ with hematuria.
- Evaluation of bladder cancer using urinary DNA methylation, NMP22, and urine cytology tests.
Main Results:
- Urinary DNA methylation test demonstrated 89.2% sensitivity and 87.8% specificity for high-grade/invasive bladder cancer.
- The test showed superior sensitivity compared to NMP22 and urine cytology for all bladder cancer stages.
- Excellent negative predictive value (97.6%) was observed, but positive predictive value was 61.3%.
Conclusions:
- The urinary DNA methylation test is a promising noninvasive biomarker for high-grade/invasive bladder cancer.
- It outperforms NMP22 and urine cytology in sensitivity, offering high specificity.
- Further research may be needed to optimize the positive predictive value for clinical application.
